← Leaderboards
Richard Casaburi
La Biomed Res Inst/ Harbor Ucla Med Ctr
$5,363,085
Attributed
$5,363,085
Total exposure
28
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $834.7K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$5,363,085 · 28
By mechanism
U10$3,155,934 · 1
M01$1,882,215 · 26
N01$324,936 · 1
Top collaborators
No co-investigators on record.
Most similar at La Biomed Res Inst/ Harbor Ucla Med Ctr
Same institution · by research overlap
- Shalendar Bhasin$66,433,688
- Ronald Sherwin Swerdloff$7,352,119
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchTestosteroneHuman SubjectUnited States National Institutes Of HealthResearch PersonnelResourcesFundingInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseSourceGrantChronic Obstructive Airway DiseaseExerciseChronic Obstructive Pulmonary DiseaseHuman Therapy EvaluationMuscle StrengthHormone TherapyMaleMuscle DisordersDouble-Blind MethodBloodHourRandomizedInflammation
Grant awards (43)
GENETIC EPIDEMIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE$230,377
M01 · FY2010 · RR · contact PI
THE EFFECT OF CHRONIC MACROLIDE ADMINISTRATION ON THE FREQUENCY AND SEVERITY OF$89,386
M01 · FY2010 · RR · contact PI
EFFECT OF MEGESTROL ACETATE AND TESTOSTERONE ON BODY COMPOSITION AND HORMONAL$39,624
M01 · FY2010 · RR · contact PI
LONG-TERM OXYGEN TREATMENT TRIAL$1,844
M01 · FY2010 · RR · contact PI
THE EFFECT OF CHRONIC MACROLIDE ADMINISTRATION ON THE FREQUENCY AND SEVERITY OF$166,605
M01 · FY2009 · RR · contact PI
GENETIC EPIDEMIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE$124,721
M01 · FY2009 · RR · contact PI
EFFECT OF MEGESTROL ACETATE AND TESTOSTERONE ON BODY COMPOSITION AND HORMONAL$59,567
M01 · FY2009 · RR · contact PI
ANTI-LEUKOTRIENE THERAPY FOR COPD EXACERBATIONS$17,683
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: THE EFFECT OF CHRONIC MACROLIDE ADMINISTRATION ON THE FREQUENCY$209,054
M01 · FY2008 · RR · contact PI
EFFECT OF MEGESTROL ACETATE AND TESTOSTERONE ON BODY COMPOSITION AND HORMONAL$8,772
M01 · FY2008 · RR · contact PI
ANTI-LEUKOTRIENE THERAPY FOR COPD EXACERBATIONS$1,463
M01 · FY2008 · RR · contact PI
MECHANISMS OF EXERCISE INTOLERANCE AND EFFECTS OF TRAINING IN CHILDREN WITH HEAE$1,463
M01 · FY2008 · RR · contact PI
LONG-TERM OXYGEN TREATMENT TRIAL: RCC$324,936
N01 · FY2007 · HL · contact PI
Strategies to Improve COPD Management$277,191
U10 · FY2007 · HL · contact PI
THE EFFECT OF CHRONIC MACROLIDE ADMINISTRATION ON THE FREQUENCY AND SEVERITY OF$43,203
M01 · FY2007 · RR · contact PI
L-GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA$7,201
M01 · FY2007 · RR · contact PI
ANABOLIC THERAPIES FOR MUSCLE DYSFUNCTION IN WOMEN WITH COPD$4,319
M01 · FY2007 · RR · contact PI
BENEFITS OF AMBULATORY OXYGEN IN HYPOXEMIC COPD PATIENTS$3,962
M01 · FY2007 · RR · contact PI
Strategies to Improve COPD Management$770,516
U10 · FY2006 · HL · contact PI
ANABOLIC THERAPIES FOR MUSCLE DYSFUNCTION IN WOMEN WITH COPD$41,139
M01 · FY2006 · RR · contact PI
L-GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA$12,467
M01 · FY2006 · RR · contact PI
BENEFITS OF AMBULATORY OXYGEN IN HYPOXEMIC COPD PATIENTS$10,597
M01 · FY2006 · RR · contact PI
Strategies to Improve COPD Management$527,085
U10 · FY2005 · HL
ANABOLIC THERAPIES FOR MUSCLE DYSFUNCTION IN WOMEN WITH COPD$78,176
M01 · FY2005 · RR
L-GLUTAMINE THEREPY FOR SICKLE CELL ANEMIA$12,610
M01 · FY2005 · RR
Strategies to Improve COPD Management$790,279
U10 · FY2004 · HL
Anabolic Therapies for Muscle Dysfunction in Women with COPD$135,436
M01 · FY2004 · RR
Sarcopenia: Testosterone Dose Response in Older Men$104,626
M01 · FY2004 · RR
Strategies to Improve COPD Management$790,863
U10 · FY2003 · HL
MUSCLE DYSFUNCTION IN OBSTRUCTIVE LUNG DISEASE$237,978
M01 · FY2001 · RR
SARCOPENIA: TESTOSTERONE DOSE RESPONSE IN OLDER MEN$237,978
M01 · FY2001 · RR
SARCOPENIA: TESTOSTERONE DOSE RESPONSE IN OLDER MEN$982
M01 · FY2000 · RR
MUSCLE DYSFUNCTION IN OBSTRUCTIVE LUNG DISEASE$982
M01 · FY2000 · RR
INHALE--Megesterol acetate in underweight COPD patients$0
M01 · FY2000 · RR
INHALE--Megesterol acetate in underweight COPD patients$0
M01 · FY2000 · RR
Therapy fo muscle dysfunction in COPD--Cellular adaptations$0
M01 · FY2000 · RR
Therapy fo muscle dysfunction in COPD--Cellular adaptations$0
M01 · FY2000 · RR
Therapy fo muscle dysfunction in COPD--Cellular adaptations$0
M01 · FY2000 · RR
SARCOPENIA: TESTOSTERONE DOSE RESPONSE IN OLDER MEN$0
M01 · FY2000 · RR
SARCOPENIA: TESTOSTERONE DOSE RESPONSE IN OLDER MEN$0
M01 · FY2000 · RR
MUSCLE DYSFUNCTION IN OBSTRUCTIVE LUNG DISEASE$0
M01 · FY2000 · RR
MUSCLE DYSFUNCTION IN OBSTRUCTIVE LUNG DISEASE$0
M01 · FY2000 · RR
INHALE--Megesterol acetate in underweight COPD patients$0
M01 · FY2000 · RR